High effectiveness of PCV13 Vaccine to Prevent Community-Acquired Pneumonia in Adults over 65

Background: CAPiTA study found significant efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) for first episode of vaccine-type community-acquired pneumonia (CAP), nonbacteremic/noninvasive vaccine-type CAP and vaccine-type CAP invasive pneumococcal disease.

Source: International Journal of Infectious Diseases - July 27, 2018 Category: Infectious Diseases Authors: G.D. Lopardo, C. Vizzotti, N. Giglio, E. Raimondo, D. Fridman, P. Micone, M. Gonzalez, D. Stamboulian Tags: UMP. 721 Source Type: research